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Summary High levels of neurotensin-like immunoreactivity were found in human small cell lung carcinoma
lines. No immunoreactivity was present in non-small cell carcinoma lines and only low amounts in post-
mortem human lung tissue. The immunoreactive material co-eluted with synthetic neurotensin on two
different chromatographic systems. No evidence was obtained for the presence of specific neurotensin binding
sites in any of the small cell carcinoma lines examined. The results suggest that small lung cell carcinoma lines
may be useful for studying the biosynthesis of human neurotensin.
Small cell carcinomas comprise approximately 20%
of all primary pulmonary malignant tumours
(Greco & Oldham, 1979). They form part of the
amine precursor uptake and decarboxylation
(APUD) system with respect to their cytochemical
properties and it is well established that cells of the
APUD series frequently produce monoamine
neurotransmitters and hormones (Le Douarin,
1982; Pearse, 1969). It is therefore not surprising
that small cell carcinomas are often associated with
the ectopic production of hormones, resulting in
paraneoplastic syndromes, such as Cushing's
disease (Richardson et al., 1978). At present, it is
unknown whether the tumour hormone production
is a simple reflection of derepression of genetic
material consequent to dedifferentiation or whether
the hormones exert a positive influence on the
growth of the tumour cells through an autocrine
mechanism (Sporn & Todaro, 1980). The latter
possibility would require the presence of hormone
receptors on tumour cell membranes. Recently, it
has become possible to establish clonable cell lines
derived from human small cell carcinomas of the
lung (Gazdar et al., 1980). Subsequently, it has
been shown that these cell lines invariably produce
high levels of material immunoreactive with
antibodies raised against the amphibian peptide
bombesin (Moody et al., 1981) and a recent study
has indicated that the immunoreactive material
probably corresponds to the mammalian peptide
gastrin-releasing peptide (Yamaguchi, 1983).
Neurotensin is a thirteen amino acid peptide
isolated from mammalian brain and small intestine
(Carraway & Leeman, 1973; Leeman & Carraway,
1982). Xenopsin is a peptide isolated from
amphibian skin that shows marked sequence
homologies with the carboxy-terminal end of
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neurotensin (Araki et al., 1973). Whereas no
xenopsin-like immunoreactivity is present in
mammalian tissues (Goedert et al., in press)
neurotensin-like immunoreactivity is found
throughout the central nervous system of mammals
(Emson etal. 1982). Inperipheral tissues, itispresentin
high concentrations in the anterior pituitary gland
and the gastrointestinal mucosa and in low
concentrations in most other tissues, including the
lung (Goedert et al., in press). Although its
physiological role is unknown at present it is likely
to function as a neurotransmitter or
neuromodulator (Nemeroff et al., 1983).
In this communication we report the presence of
high concentrations of neurotensin-like
immunoreactivity (NTLI) and the absence of
xenopsin-like immunoreactivity (XPLI) and of
neurotensin receptors in all small cell lung
carcinoma lines examined. NTLI could not be
detected in non-small cell lung carcinoma lines and




The small cell lung cancer lines MAR, POC and
FRE were kindly donated by Dr M. Ellison,
Ludwig Institute for Cancer Research, Sutton,
England. The line NCI-H69 was a gift from Dr D.
Carney, National Cancer Institute, Bethesda, USA.
The small cell lung cancer culture COR/L32 and
non-small cell lung cancer cultures COR/L26 and
COR/L23 were derived by Dr P.R. Twentyman
(MRC Clinical Oncology and Radiotherapeutics
Unit, MRC Centre, Cambridge, U.K.) from clinical
samples. Full details of the morphological and
biochemical characteristics of these cultures will be
described elsewhere (Twentyman et al., in
preparation). Post-mortem lung tissue was obtained
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from four elderly patients who had died of non-
pulmonary diseases (the time elapsed between the
death of the patients and the removal of the tissues
amounted to 20-48h). The tumour cells were
grown as multicellular spheroids which were
disaggregated mechanically without prior enzymic
digestion.
Radioimmunoassay
For extraction, small cell lung carcinoma cell pellets
and post-mortem human lung tissue were placed
into boiling 1 M acetic acid for 10min,
homogenised with a glass-teflon homogeniser and
allowed to stand at room temperature for 20min in
order to ensure complete extraction. Aliquots were
removed for protein determinations, the
homogenates spun at 3,000g for 20min and the
supernatants freeze-dried. The lyophilised extracts
were resuspended in assay buffer, centrifuged at
2,000g for 10min in order to remove insoluble
material and assayed in duplicate at several
dilutions using antisera directed against the amino-
and carboxy-terminus end of neurotensin and
against the amphibian peptide xenopsin, as
described previously (Emson et al., 1982; Goedert
et al., in press). For the characterisation of the
immunoreactive material, lyophilised tissue extracts
were reconstituted in 4-5ml and applied to a
Sephadex G-25 column (1.6 x 90cm), equilibrated
and eluted at room temperature with 0.1 M acetic
acid. Fractions (3ml) were collected at a flow-rate
of 15mlh-1; these were lyophilised, resuspended in
assay buffer and assayed using antisera directed
against the amino- and carboxy-terminus of
neurotensin. The material corresponding to the
NTLI peak was subjected to HPLC on reverse
phase using a p Bondapak C18 column
(0.39 x 30cm). A flow-rate of 2mlmin- was used
and elution achieved by using a 20min linear
gradient of 5-35% (v/v) acetonitrile with 10mM
ammonium acetate, pH 4.5, as the aqueous phase.
Following lyophilisation the fractions were assayed
for neurotensin by using amino- and carboxy-
terminus directed antisera. Proteins were
determined according to Lowry et al. (Lowry et al.,
1951), using bovine serum albumin as the standard.
Immunohistochemistry
Cells were centrifuged at 600 rpm onto poly-L-
lysine coated slides and fixed in parabenzoquinone.
They were stained by using a modification of the
indirect immunofluorescence technique (Gu et al.,
1983). Briefly, they were incubated at 4°C for 24h
with a rabbit antiserum raised against neurotensin
(diluted 1:500) (Goedert et al., 1983). Following
washing in 50mM phosphate buffered saline the
cells were re-exposed to the primary antibody at
25°C for 2h. NTLI-positive cells were visualised by
subsequent incubation with fluorescein-
isothyocyanate-conjugated goat anti-rabbit IgG
(diluted 1: 10, 30min, 25°C). Controls included pre-
adsorption of the diluted primary antiserum with
20pgml-1 of synthetic neurotensin, the use of
preimmune serum and the omission of the first
antibody.
Receptor binding assay
Small cell carcinoma cells were homogenised with a
glass-teflon homogeniser in 50mM Tris-HCl buffer,
pH 7.4. Following centrifugation at 50,000g for
20min, they were resuspended in 50mM Tris-HCl,
rehomogenised and allowed to stand at 37°C for
30min. After a 20min centrifugation at 50,000g
they were resuspended in 10ml 50mM Tris-HCl
homogenised, aliquots removed for protein
determinations and diluted in 50mM Tris-HCl
containing 1 mM EDTA, 0.1% bovine serum
albumin and 40mg -1 bacitracin to yield a tissue
protein concentration of 0.7mgml1 Binding assays
were performed by incubating the washed
membranes in 2nM [3,1l-Tyrosyl-3,5-3H]-
neurotensin (New England Nuclear,
56.4Cimmol-1) for 10min at 25°C. Non-specific
binding was defined as binding in the presence of
1 uM neurotensin (Cambridge Research
Biochemicals). At the end of the incubation time
the membranes were quickly filtered through GF/B
glass fibre filters (Whatman) pretreated with 0.2%
polyethyleneimine, washed with four times 5ml of
incubation buffer and the radioactivity was
determined by liquid scintillation spectrometry. A
detailed description of the binding assay will be
published elsewhere (Goedert et al., in press).
Results
High levels of NTLI were present in extracts of all
the small-cell carcinoma cell lines investigated
(Table I). The immunoreactive material was
characterised further by gel filtration on a
Sephadex G-25 column (Figure la) and on reverse-
phase HPLC (Figure lb). With both systems, the
immunoreactivity emerged as a single peak in the
same position as synthetic neurotensin, and could
be detected in equivalent amounts using both
carboxy- and amino-terminal directed
radioimmunoassays. The amphibian peptide
xenopsin could not be detected in any of the small
cell carcinoma lines (Table I). Neurotensin-positive
cells were visualised using an antiserum directed
against the carboxy-terminal end of the molecule by
indirect immunofluorescence. Numerous
neurotensin-positive cells were present and theNEUROTENSIN IN SMALL CELL LUNG CANCER 181
Table I Levels of neurotensin- and xenopsin-like immunoreactivity and of specific neurotensin binding sites in small cell
lung carcinoma lines (SCLC) and in human lung tissue
Neurotensin-like Xenopsin-like Specific neurotensin
immunoreactivity immunoreactivity binding sites
Tissues (fmolmg-1 protein) (fmolmg 1 protein) (fmol mg-1 protein)
SCLC POC 4590+520 (4) <0.1 (3) <2 (2)
SCLC COR/L32 4030+376 (3) ND ND
SCLC FRE 1280± 150 (3) <0.1 (3) <2 (2)
SCLC NCI H69 1030+100 (6) <0.1 (4) <2 (2)
SCLC MAR 870+100 (4) <0.1 (4) <2 (2)
COR/L26 <22 (3) ND ND
COR/L23 <33 (2) ND ND
Lung tissue 13+ 2 (4) <0.1 (2) ND
The values represent the mean+s.e. of the number ofdeterminations indicated in parentheses.
ND=not determined.
.... ..................
Figure 1 (a) Fractionation of the neurotensin-like
immunoreactivity in an acetic acid extract of the small
cell carcinoma cell line POC on a Sephadex G-25
column. The column was calibrated by blue dextran
(void volume, Vo), synthetic neurotensin (NT(1-13))
and 22NaCl (total volume, Vt). (b) The immunoreact-
ive peak was subjected to high performance liquid
chromatography on reverse phase using a linear 5-
35% acetonitrile gradient. Fractions were assayed
using antisera directed against the neurotensin amino-
terminus (0) and carboxy-terminus (A).
staining was completely abolished by preadsorption
of the diluted primary antiserum with 20/pgml-1
synthetic neurotensin (Figure 2). No staining was
observed with preimmune rabbit serum or when the
primary antiserum was omitted. In contrast to the
small-cell carcinoma cell lines only very low levels
of NTLI were found in post-mortem human lung
tissue and no NTLI was detectable in non-small cell
carcinoma cell lines (Table I). Some of the small-
cell carcinoma lines were investigated for the
presence of neurotensin receptors by using a test-
tube binding assay. No evidence was found for the
presence of neurotensin receptors in any of the
small cell carcinoma cell lines investigated
(<2fmol mg- 1 protein) (Table I).
Discussion
The present results indicate that high levels of
NTLI are present in all the human small cell lung
carcinoma lines investigated and that the
immunoreactive material is indistinguishable from
synthetic neurotensin on two chromatographic
systems. Indirect immunofluorescence has shown
that NTLI is found in a substantial percentage of
the small cells, where it is presumably present in
neurosecretory granules. When expressed per mg
protein the amounts of NTLI in small cells are
comparable to the levels present in the
hypothalamus and the ileum, the two richest
sources of NTLI in mammals (Emson et al., 1982;
Goedert et al., in press). Conversely, no NTLI was
found in two non-small cell lung carcinoma lines
and the NTLI levels in post-mortem human lung
tissue were two orders of magnitude lower than in
the small cell lung carcinoma lines; it has been
shown previously that NTLI is stable post-mortem
in both central and peripheral rat tissues (Emson et
al., in press). As for gastrin-releasing peptide182 M. GOEDERT et al.
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Figure 2 (a) Cells in the human small cell lung carcinoma line POC containing neurotensin-like im-
munoreactivity demonstrated by indirect immunofluorescence. (b) Staining following pre-adsorption of the
diluted neurotensin antiserum with 20ugml-1 synthetic neurotensin.
(Yamaguchi et al., 1983), it is the mammalian
peptide neurotensin and not the structurally related
amphibian peptide xenopsin that is present in the
small cell lung carcinoma lines. No evidence was
obtained for the presence of neurotensin receptors
in the small cell carcinoma lines, which would not
support a paracrine mode of action for neurotensin
in these cell lines. The possible function of NTLI in
human small cell carcinomas is unknown at
present. It is conceivable that the immunoreactive
material is released into the general circulation
where it may be implicated in the pathogenesis of
paraneoplastic syndromes.
Previously, NTLI has been shown to be present
in endocrine pancreatic tumours (Blackburn et al.,
1980; Feurle et al., 1981; Gutniak et al., 1980;
Theodorsson-Norheim et al., 1983) and it also was
found in human small cell lung carcinomas (Wood
et al., 1981, 1983). At present, the only cell lines
known to produce NTLI have been derived from a
rat medullary carcinoma of the thyroid and a rat
phaeochromocytoma (Tischler et al., 1982;
Zeytinoglu et al., 1980). Our findings constitute
the first example of cell lines of human origin
producing NTLI. It should now be possible to
study the factors involved in the biosynthesis of
human neurotensin and the small cell lung
carcinoma lines may constitute a favourable
material for elucidating the structure of the human
neurotensin gene.
References
ARAKI, K., TACHIBANA, M., UCHIYAMA, T., NAKAJIMA,
T. & YASUHARA, T. (1973). Isolation and structure of
a new active peptide, Xenopsin, on smooth muscle,
especially on a strip of fundus from a rat stomach
from the skin of Xenopus laevis. Chem. Pharm. Bull.,
21, 2801.
BLACKBURN, A.M., BRYANT, M.G., ADRIAN, T.E. &
BLOOM, S.R. (1980). Pancreatic tumours produce
neurotensin. J. Clin. Endocrinol. Metab., 52, 820.
CARRAWAY, R. & LEEMAN, S.E. (1973). The isolation of
a new hypotensive peptide, neurotensin, from bovine
hypothalami. J. Biol. Chem., 248, 6854.
EMSON, P.C., GOEDERT, M., HORSFIELD, P., RIOUX, F. &
ST PIERRE, S. (1982). The regional distribution and
chromatographic characterisation of neurotensin-like
immunoreactivity in the rat central nervous system. J.
Neurochem., 38, 992.
EMSON, P.C., HORSFIELD, P., GOEDERT, M., ROSSOR,
M.N. & HAWKES, C.H. Neurotensin in human brain:
regional distribution and effects of neurological illness.
Brain Res. (in press).
FEURLE, G.E., HELMSTAEDTER, V., TISCHBIREK, K. & 4
others. (1981). A multihormonal tumor of the pancreas
producing neurotensin. Dig. Dis. Sci., 26, 1125.
GAZDAR, A., CARNEY, D.N., RUSSEL, E.K. & 5 others.
(1980). Establishment of continuous, clonable cultures
of small cell carcinoma of the lung which have amine
precursor uptake and decarboxylation cell properties.
Cancer Res., 40, 3502.
GOEDERT, M., MANTYH, P.W., HUNT, S.P. and EMSON,
P.C. (1983). Mosaic distribution of neurotensin-like
immunoreactivity in the cat striatum. Brain Res., 274,
176.NEUROTENSIN IN SMALL CELL LUNG CANCER 183
GOEDERT, M., PITTAWAY, K., WILLIAMS, B.J & EMSON,
P.C. Specific binding of triatiated neurotensin to rat
brain membranes: characterisation and regional
distribution. Brain Res. (in press).
GOEDERT, M., STURMEY, N., WILLIAMS, B.J. & EMSON,
P.C. The regional distribution of xenopsin- and
neurotensin-like immunoreactivity in Xenopus laevis
and rat tissues. Brain Res. (in press).
GRECO, F.A. & OLDHAM, R.K. (1979). Small-cell lung
cancer. N. Engl. J. Med., 301, 355.
GU, J., ISLAM, K.N. & POLAK, J.M. (1983). Repeated
application of first layer antiserum improves
immunofluorescence staining: a modification of the
indirect immunofluorescence staining procedure.
Histochem. J., 15, 475.
GUTNIAK, M., ROSENQUIST, U., GRIMELIUS, L. & 8
others. (1980). Report on a patient with watery
diarrhoea syndrome caused by a pancreatic tumour
containing neurotensin, enkephalin and calcitonin.
Acta Med. Scand., 208, 95.
LEEMAN, S.E. & CARRAWAY, R. (1982). Neurotensin:
discovery, isolation, characterization, synthesis and
possible physiological roles. Ann. N.Y. Acad. Sci., 400,
1.
LE DOUARIN, N. (1982). The Neural Crest. University
Press: Cambridge.
LOWRY, O.H., ROSEBROUGH, N.J., FARR, A.L. &
RANDALL, R. (1951). Protein measurement with the
Folin phenol reagent. J. Biol. Chem., 193, 265.
MOODY, T.W., PERT, C.B., GAZDAR, A.F., CARNEY, D.N.
& MINNA, J.D. (1981). High levels of intracellular
bombesin characterize human small cell lung
carcinoma. Science, 214, 1246.
NEMEROFF, C.F., LUTTINGER, D. & PRANGE, A.J. (1983).
Neutrotensin and bombesin. Handbook of
Psychopharmacology vol. 16, (Eds. Iversen et al.). New
York: Plenum Press, p. 363.
PEARSE, A.G.E. (1969). The cytochemistry and
ultrastructure of polypeptide hormone-producing cells
of the APUD series and the embryologic, physiologic
and pathologic implications of the concept. J.
Histochem. Cytochem., 17, 303.
RICHARDSON, R.L., GRECO, F.A., OLDHAM, R.K. &
UDDLE, G.W. (1978). Tumor products and potential
markers in small cell lung cancer. Semin. Oncol., 5,
253.
SPORN, M.B. & TODARO, G.J. (1980). Autocrine secretion
and malignant transformation of cells. N. Engl. J.
Med., 303, 878.
THEODORSSON-NORHEIM, E., OBERG, K., ROSELL, S. &
BOSTROM, H. (1983). Neutrotensin-like
immunoreactivity in plasma and tumor tissue from
patients with endocrine tumors of the pancreas and
gut. Gastroenterology, 85, 881.
TISCHLER, A.S., LEE, Y.C., SLAYTON, V.W. & BLOOM,
S.R. (1982). Content and release of neurotensin in
PC12 phaechromocytoma cell cultures: modulation by
dexamethasone and nerve growth factor. Regul. Pept.,
3, 415.
WOOD, S.M., WOOD, J.R., GHATEI, M.A., LEE, Y.C.,
O'SHAUGHNESSY, D. & BLOOM, S.R. (1981).
Bombesin, somatostatin and neurotensin-like
immunoreactivity in bronchial carcinoma. J. Clin.
Endocrinol. Metab., 53, 1310.
WOOD, J.R., WOOD, S.M., LEE, Y.C. & BLOOM, S.R. (1983).
Neurotensin-secreting carcinoma of the bronchus.
Postgrad. Med. J., 59, 46.
YAMAGUCHI, K., ABE, K., KAMEYA, T. & 4 others.
(1983). Production and molecular size heterogeneity of
immunoreactive gastrin-releasing peptide in fetal and
adult lungs and primary lung tumors. Cancer Res., 43,
3932.
ZEYTINOGLU, F.N., GAGEL, R.F., TASHJIAN, A.H.,
HAMMER, R.A. & LEEMAN, S.E. (1980).
Characterization of neurotensin production by a line
of rat medullary thyroid carcinoma cells. Proc. Natl.
Acad. Sci., 77, 3741.
B.J.C.- C